Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
42.33
+0.29 (+0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
26
27
Next >
Why Shares Of Eli Lilly And Biogen Are Rallying Today
November 14, 2022
Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment.
Via
Benzinga
Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s Disease
November 14, 2022
From
Genentech
Via
Business Wire
Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs
November 03, 2022
From
Genentech
Via
Business Wire
Biogen To Report Q3 Earnings: Here's What To Expect
October 21, 2022
Biogen will report third-quarter 2022 results on Oct 25, before market open.
Via
Talk Markets
6 ETFs That Are All You Need for Retirement
October 30, 2022
These yield-producing stock and bond funds are all down less than the S&P 500 this year.
Via
The Motley Fool
15 Global Psychedelics Executives To Keep An Eye On In 2022
October 28, 2022
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list...
Via
Benzinga
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
October 28, 2022
By Jad Malaeb, Benzinga
Via
News Direct
Topics
ETFs
Stocks
Exposures
US Equities
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
October 28, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones Industrial Average...
Via
TheNewswire.com
Topics
ETFs
Stocks
Exposures
US Equities
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
October 27, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022.
Via
Benzinga
Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)
October 27, 2022
From
Genentech
Via
Business Wire
Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile
October 26, 2022
From
Genentech
Via
Business Wire
Analyst Bullish On SQZ Biotech's Technology For Solving Cell Therapy Challenges
October 20, 2022
Via
Benzinga
Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022
October 19, 2022
From
Genentech
Via
Business Wire
Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide
October 18, 2022
Via
Benzinga
Market Sentiment Improves Amid Earnings Season
October 18, 2022
The fourth quarter started on a sour note as geopolitical tensions and recession fears triggered a risk-averse mood, but earnings season has started since then, focusing market participants’ attention...
Via
Talk Markets
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
October 15, 2022
Deals, financings, trials and approvals on the China biotech/pharma market.
Via
Talk Markets
Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts
October 13, 2022
Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's.
Via
Benzinga
Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity
October 13, 2022
Even a percentage of the Alzheimer's market could mean $7 billion for Biogen.
Via
Investor's Business Daily
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
October 12, 2022
Via
Benzinga
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests
October 12, 2022
Via
Benzinga
Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
October 12, 2022
From
Genentech
Via
Business Wire
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
Via
Benzinga
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
October 03, 2022
Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California.
Via
Benzinga
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
September 30, 2022
The major indexes fell, with the S&P 500 breaking below bear market lows.
Via
Investor's Business Daily
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
September 28, 2022
Via
Benzinga
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
September 28, 2022
Via
Benzinga
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data
September 28, 2022
Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd.
Via
Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
September 27, 2022
Via
Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
September 23, 2022
The World Health Organization (WHO) warned that it struggles to identify and
Via
Benzinga
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger
September 19, 2022
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.